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Abstract (150 words) 
 
 
Amyotrophic lateral sclerosis is a devastating neurodegenerative disease. The mechanism that 
underlies ALS pathology remains unclear, but protein inclusions are associated with all forms 
of the disease. Apart from pathogenic proteins, such as TDP-43 and SOD1, other proteins are 
associated with ALS inclusions including small heat shock proteins. However, whether small 
heat shock proteins have a direct effect on SOD1 aggregation remains unknown. In this study 
we have examined the ability of small heat shock proteins B-crystallin and Hsp27 to inhibit 
the aggregation of SOD1 in vitro. We show that these chaperone proteins suppress the  
increase in thioflavin T fluorescence associated with SOD1 aggregation primarily through 
inhibiting aggregate growth, not the lag phase in which nuclei are formed. B-crystallin 
forms high molecular mass complexes with SOD1 and binds directly to SOD1 aggregates. 
Our data are consistent with an overload of proteostasis systems being associated with 
pathology in ALS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
Introduction 
 
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that is 
characterised by the progressive and selective death of upper and lower motor neurons, 
leading to loss of muscle control, muscle atrophy and invariably death, generally within 3-5 
years of diagnosis. Neurodegeneration in ALS has been attributed to a variety of processes 
including glutamate excitotoxicity, oxidative stress, disruption of neurofilaments and axonal 
transport, protein aggregation, mitochondrial dysfunction, endoplasmic reticulum stress, and 
(most recently) dysfunctional RNA metabolism (Pasinelli & Brown 2006).  Although the 
cause of sporadic forms of ALS remains a mystery, there is a rapidly growing list of genes in  
which mutations cause familial ALS (fALS; accounting for 5-10% of all ALS cases). These 
include SOD1 (Rosen et al. 1993), alsin (Yang et al. 2001), senataxin (Chen et al. 2004), 
FUS/TLS (Kwiatkowski et al. 2009; Vance et al. 2009), VAPB (Nishimura et al. 2004), TDP-
43 (Kabashi et al. 2008; Sreedharan et al. 2008), optineurin (Maruyama et al. 2010), VCP 
(Johnson et al. 2010) and c9orf72 (DeJesus-Hernandez et al. 2011). In common with other 
neurodegenerative diseases, such as Alzheimer’s disease, Creutzfeldt-Jakob disease, 
Parkinson’s disease, and Huntington’s disease, there is growing evidence that protein 
aggregates are closely associated with degeneration in all forms of ALS (Leigh et al. 1991; 
Ticozzi et al. 2010). Indeed, there are some that consider ALS a proteinopathy (Strong et al. 
2005).   
 
The best-studied fALS cases are from families possessing mutations in the gene encoding 
copper/zinc superoxide dismutase (Cu/Zn SOD, SOD1). There are over 140 different 
mutations dispersed over the whole sequence of the SOD1 gene that can cause ALS. What 
these mutations have in common is the ability to destabilise the structure of the protein, 
shortening its half-life (Borchelt et al. 1994) and increasing its propensity to aggregate into 
oligomeric forms (Banci et al. 2007) and form insoluble material in cells (Prudencio et al. 
2009). Predictions using the Chiti-Dobson equation (that predicts aggregation propensity) 
have suggested that protein instability and aggregation propensity is a risk factor for SOD1 
associated fALS (Wang et al. 2008b).  It is thought that the mutant versions of SOD1 never  
realise their proper native structure, and therefore can cause cellular malfunction if they are 
not rapidly removed (Hart 2006). In vitro SOD1 follows a two phase kinetic model of 
aggregation that is common to most amyloid forming proteins, which includes a (rate-
limiting) lag phase in which oligomeric nuclei are formed, followed by a rapid growth phase 
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and subsequent plateau phase in which aggregate growth has reached an equilibrium 
(Chattopadhyay et al. 2008).  
 
Although mutant SOD1 is aggregation prone, it is maintained in a soluble form in young mice 
(Wang et al. 2009). This is presumably due to the efficient network of processes in place in 
cells to maintain protein homeostasis (proteostasis). It is thought that with aging these 
proteostasis systems can become overloaded or defective, resulting in persistent deposits of 
aggregated protein associated with disease pathology (Ben-Zvi et al. 2009). Aggregates of 
SOD1 are found in motor neurones and astrocytes in fALS patients and mutant SOD1 
expressing mice (Bruijn et al. 1998). The accumulation of this misfolded protein signifies a  
breakdown in the quality control system that prevents protein aggregation or an inability of 
these systems to cope with the increased load brought about by mutant SOD1 expression in 
ALS (Wang et al 2009). There are many other proteins associated with SOD1 deposits in vivo 
including molecular chaperones HSP70 and B-crystallin, and structural proteins such as 
vimentin, neurofilament heavy chain and tubulin (Bergemalm et al. 2010). The reason why 
these proteins are present in these deposits is unknown, however, it has been proposed that, at 
least in the case of chaperones, it may signify their failed attempt to keep the aggregating 
protein soluble in solution (Muchowski & Wacker 2005). 
 
The small heat shock proteins (sHsps) B-crystallin and Hsp27 are of particular interest  
because they co-localise with astrocytic inclusions in humans (Kato et al. 1997), and both 
Hsp25 (the mouse ortholog of human Hsp27) and B-crystallin increase in abundance in the 
spinal cord as ALS progresses in mouse models (Vleminckx et al. 2002; Wang et al. 2008a; 
Wang et al. 2005).  B-crystallin and Hsp25 have also been identified as components of 
inclusions from mutant SOD1 (G127X, G93A, D90A and G37R) mice using proteomics 
techniques on isolated inclusions (Bergemalm et al 2010) and detergent insoluble fractions 
(Basso et al. 2009). Moreover, SOD1 can be immunoprecipitated using B-crystallin 
antibodies in cell models of SOD1 associated ALS (Shinder et al. 2001). In HEK293 cells over-
expression of B-crystallin has been shown to suppress mutant SOD1 aggregation (Karch & 
Borchelt 2010), and B-crystallin has been shown to inhibit the movement of SOD1 into the  
insoluble fraction of tissue homogenates from mutant SOD1 mice when incubated at 37
o
C 
(Wang et al 2005). Hsp27 has been shown to protect cultured neurons from SOD1 
proteotoxicity (Patel et al. 2005) but this conflicts with work in cell culture models that reports 
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that Hsp27 over-expression does not protect Neuro2a cells from SOD1-associated toxicity 
(Krishnan et al. 2006). In animal models, knock-down of B-crystallin does not affect the 
amount of insoluble SOD1 nor does it significantly alter lifespan of transgenic mice (Karch & 
Borchelt 2010). Similarly, while over-expression of Hsp27 slows the early phase of disease it 
does not alter lifespan of SOD1 mice (Sharp et al. 2008). This may be, at least in part, due to 
the fact that robust expression of B-crystallin and Hsp25 is largely restricted to glial cells. 
However, there have been no studies that have investigated whether B-crystallin or Hsp27 
directly interact and suppress the aggregation of SOD1 outside of the complex cellular milieu. 
The aim of this work was therefore to examine the ability and mechanism by which the sHsps 
B-crystallin and Hsp27 suppress SOD1 aggregation in vitro.   
 
 
Results and Discussion 
 
Previous work has demonstrated that SOD1 is aggregation prone in its apo and disulphide 
reduced state (Chattopadhyay et al 2008; Furukawa et al. 2008). Moreover, a large proportion 
of human mutant SOD1 is found to exist in a demetallated and reduced form in transgenic 
mouse models (Jonsson et al. 2006). In the current study we have used DTT and EDTA to 
reduce the disulphide bonds and remove bound metal ions to promote aggregation of SOD1. 
We observed that, under the conditions used in this study, there was no increase in ThT  
fluorescence associated with WT SOD1 until high concentrations of DTT (50 mM) were used 
(Figure 1A). In the presence of 50 mM DTT, WT SOD1 aggregation was defined by a lag 
phase of ~5 h and maximum ThT fluorescence was reached after ~10 h of incubation. 
Similarly, G93A SOD1 aggregation was dependent on the presence of DTT, however, lower 
concentrations (10 mM) were required to initiate aggregation (Figure 1B). This is consistent 
with work that shows that native state of G93A SOD1 is more destabilised than WT SOD1 
(Svensson et al. 2010). However, when high concentrations of DTT were used (50 mM), the 
rate of aggregation of G93A SOD1 was very similar to WT SOD1 under the same conditions. 
This indicates that while the SOD1 mutations destabilise the native conformation, when WT 
SOD1 is destabilised by extreme conditions it will aggregate at a similar rate.  These data are  
consistent with computational (Wang et al 2008b) and cell culture models (Prudencio et al 
2009), that indicate a correlation between aggregation propensity of SOD1 and disease 
severity.. 
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Previous studies have reported that although over-expression of B-crystallin can reduce 
insoluble aggregate formation in cell models of SOD1 aggregation, knock-down of B-
crystallin in a G93A SOD1 mouse model of ALS does not affect the total amount of insoluble 
protein measured (Karch & Borchelt 2010). As a result, it was not clear if the suppression of 
aggregation in cell models was due to a direct role in halting aggregation or whether boosting 
the capacity of the cell’s proteostasis machinery was enough to quell aggregation. In order to 
test whether sHsps could indeed directly suppress SOD1 aggregation we used our in vitro 
aggregation assay and recombinant forms of B-crystallin and Hsp27. Co-incubation of 
G93A SOD1 with B-crystallin resulted in a significant decrease in ThT fluorescence 
associated with SOD1 aggregation (Figure 2A) but it did not alter the lag phase (which  
remained at ~ 5 h in the presence or absence of B-crystallin). These results are consistent 
with B-crystallin having a direct role in suppressing SOD1 aggregation in cell models over-
expressing B-crystallin. The lack of an obvious change in phenotype upon knockout of B-
crystallin in the G93A SOD1 mouse model of ALS may be attributable to the overlap in 
chaperone function of the small heat shock proteins, i.e. other members of the sHsp family 
may have compensated for the loss of B-crystallin in these mice.  Alternatively, B-
crystallin may not be expressed at sufficient levels in neurons where SOD1 aggregation 
occurs in these mice. In support of this, it is well documented that B-crystallin expression in 
motor neurones is low in comparison to surrounding glia (Vleminckx et al 2002) and the 
initial stages of SOD1 aggregation occurs in motor neurones in mice (Stieber et al. 2000).   
 
We next tested whether the Hsp27 is also able to inhibit G93A SOD1 aggregation in vitro. As 
seen for B-crystallin, co-incubation of G93A SOD1 with Hsp27 resulted in a decrease in 
ThT fluorescence associated with SOD1 aggregation (Figure 2B). Again, the presence of 
Hsp27 did not significantly alter the lag phase. However, at a molar ratio of 1:0.01 
(SOD1:chaperone) Hsp27 was significantly less effective at inhibiting G93A SOD1 
aggregation when compared to B-crystallin (B-crystallin 78 ± 5% compared to Hsp27 54 ± 
6%, p<0.05). This data indicates that the ability of Hsp27 to suppress SOD1 proteotoxicity in 
cultured neurons (Patel et al 2005) is likely to be attributable to the chaperone activity of 
Hsp27. This is consistent with increased survival of motor neurons in early stage disease in  
Hsp27 over-expressing SOD1 mice (Sharp et al 2008).  The lack of an effect on longevity in 
this model is most likely attributable to an overwhelming of the chaperone: as disease 
progressed Hsp27 levels in motor neurons decreased (Sharp et al 2008).  
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Previous cell culture experiments have detected the formation of stable complexes between 
G93A SOD1 aggregates and αB-crystallin, however, it was unclear whether this interaction 
was a direct one or mediated through another (unidentified) factor (Shinder et al 2001). The 
binding of sHsps to SOD1 aggregates may account, at least in part, for the depleted levels of 
Hsp25 reported in the cytosolic fractions of motor neurons in G93A SOD1 mice (Maatkamp 
et al. 2004). Stable complexes between SOD1 and sHsps may also explain the presence of 
Hsp25 and αB-crystallin in the insoluble fractions of spinal cord extracts from transgenic 
mice with ALS symptoms (Wang et al 2008a; Wang et al 2005). Therefore, to test if B-
crystallin is capable of binding directly to SOD1 and forming a stable complex with it, we  
incubated WT SOD1 with 50 mM DTT in the absence or presence of B-crystallin. 
Aggregation of WT SOD1 when incubated alone was more rapid in this assay than seen 
previously (compare the green line in Figure 1A with the blue line in Figure 3A) due to the 
increased rate of shaking used for this assay, i.e. 300 revolutions per minute (rpm) versus 120 
rpm. The rate of agitation is known to play a significant role in the kinetics of aggregation due 
to it promoting nuclei formation and therefore secondary nucleation (Knowles et al 2009; Xue 
et al 2008). Addition of B-crystallin resulted in a concentration-dependent decrease in ThT 
fluorescence associated with WT SOD1 aggregation, such that, a molar ratio of 1:1 
(SOD1:B-crystallin), there was nearly complete inhibition (Figure 3A). Size exclusion 
chromatography and SDS-PAGE of the fractions eluting from the column demonstrated that,  
prior to incubation, SOD1 elutes as a single peak at an elution volume of 15.8 mL, consistent 
with its dimeric form in the native state (Figure 3B). B-crystallin primarily elutes as a broad 
peak centred at an elution volume of 11.1 mL due to its polydisperse oligomeric state (Haley 
et al 1998). The sample containing both WT SOD1 and B-crystallin (at a 1:1 molar ratio) 
eluted primarily as a very broad peak centred at an elution volume of 10.8 mL. This peak 
contains both SOD1 and B-crystallin. Moreover, there was a decrease in intensity of the 
dimeric SOD1 peak (i.e. at an elution volume of 15.8 mL). These data are consistent with the 
formation of a high molecular mass complex between SOD1 and B-crystallin. The 
formation of a high molecular mass complex between B-crystallin and aggregating proteins 
reflects the well-described ‘holdase’ type chaperone mechanism of sHsps and is thought to  
enable a maintenance of aggregating protein in solution (Ecroyd & Carver 2009).  
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Taken together, our observations are consistent with the sHsps inhibiting SOD1 aggregation 
through an effect upon the growth phase of the aggregation kinetics rather than upon the lag 
phase. That is, while both B-crystallin and Hsp27 significantly reduced the extent of SOD1 
aggregation, the lag phase of the reaction was not significantly changed in the presence or 
absence of the chaperones (see Figure 2 and Figure 3A). If a two-phase kinetic model is used 
to model the aggregation process of SOD1, these data imply that both Hsp27 and αB-
crystallin inhibit SOD1 aggregation by acting primarily upon fibril elongation rather than the 
formation of fibril nuclei. Thus, our data suggests that sHsps bind to larger oligomeric species 
formed during SOD1 aggregation rather than partially folded monomers and pre-nuclei 
oligomers. Such a mechanism is consistent with recent work in which αB-crystallin has been  
reported to be capable of binding to preformed fibrils and, in doing so, suppress further fibril 
formation (Shammas et al. 2011; Waudby et al. 2010). Moreover, in both humans and mouse 
models of ALS, B-crystallin is primarily associated with the insoluble inclusions (Basso et 
al 2009; Bergemalm et al 2010; Kato et al 1997). Thus, we directly tested whether B-
crystallin is capable of binding to mature SOD1 aggregates using a dot blot assay (Figure 3C). 
After centrifugation and washing, a proportion of aggregated SOD1 could be detected in the 
pellet (P). In contrast, when aggregated WT SOD1 and B-crystallin were incubated together 
B-crystallin was also detected in the pellet (P) fraction, consistent with it binding to 
aggregated SOD1. There was no apparent difference in the amount of SOD1 in the pellet 
fraction when B-crystallin was incubated with this aggregated sample. The ability of B- 
crystallin to bind to aggregated forms of SOD1 may, at least in part, explain the presence of 
B-crystallin in SOD1 positive inclusions in ALS patients and its association with inclusions 
in mouse models.  
  
In summary the in vitro model of SOD1 aggregation used in this study has provided evidence 
that the sHsps B-crystallin and Hsp27 can directly interact with and inhibit SOD1 
aggregation. These findings, along with those that show that upregulation of sHsps (and other 
chaperones, such as Hsp70) protect against SOD1 proteotoxicity (Gifondorwa et al. 2007; 
Kalmar et al. 2012; Sharp et al 2008) raises the question as to why inclusion formation still 
occurs in vivo. A possible explanation is that systems that normally act to maintain  
proteostasis are overloaded by the increased burden brought about by SOD1 aggregation, or 
the decrease in the soluble pool of chaperone proteins that occurs because of this, or both. It is 
important to note that the aggregation assays in this study were exclusively conducted under 
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reducing conditions. While disulfide bond reduction is thought to be an important step in the 
monomerisation and subsequent aggregation of SOD1 (Chattopadhyay et al 2008; Karch et al. 
2009), several theories of SOD1 toxicity focus upon oxidative stress as an important factor in 
ALS pathogenesis (Pasinelli & Brown 2006). Moreover, previous studies with G93A SOD1 
mice have identified heterogeneous SOD1 aggregates which varied in form with disease 
progression (Sasaki et al. 2005). Given that different reaction conditions (in vitro) have been 
reported to produce differing species of SOD1 aggregates (Chattopadhyay et al 2008; Rakhit 
et al. 2002; Stathopulos et al. 2003) it is possible that the cellular conditions and aggregation 
pathway also vary with disease progression. This may, at least in part, explain the 
contradictory reports of protection from sHsps in the literature.  
 
While the rapid and predictable progression of SOD-related ALS confirms the ability of toxic 
G93A SOD1 species to evade in vivo proteostatic systems, the mechanism by which G93A 
SOD1 evades these systems remains unknown. This study was able to confirm the ability of 
Hsp27 and αB-crystallin to inhibit G93A SOD1 aggregation in vitro. Since previous studies 
have suggested that overexpression of chaperones is insufficient to attenuate the progression 
ALS in mouse models (Krishnan et al. 2008) further investigation to clarify the mechanism by 
which mutant SOD1 escapes the proteostatic machinery might provide clues to a possible 
treatment for ALS. 
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Figure legends 
 
Figure 1 – The reduction-dependent aggregation of SOD1 in vitro. Wild-type (a) or G93A 
(b) SOD were incubated at 30 M in 10 mM potassium phosphate buffer containing 5 mM 
EDTA, pH 7.4 whilst shaking (300 rpm for 5 min each cycle, 15 min cycles) at 37ºC in the 
absence (red) or presence of 10 mM (blue) or 50 mM (green) DTT. The buffer alone sample 
is also shown (orange). The amount of ThT fluorescence (excitation at 440 nm and emission 
at 490nm) was monitored over time using a microplate-reader and the change in ThT 
fluorescence is reported as a mean ± SEM of three replicates. The data is representative of 3 
independent experiments.  
 
Figure 2 -  The small heat shock proteins B-crystallin and Hsp27 inhibit the in vitro 
aggregation of G93A SOD1. G93A SOD1 was incubated at 30 M in 10 mM potassium 
phosphate buffer containing 5 mM EDTA, pH 7.4 whilst shaking (300 rpm for 5 min each 
cycle, 15 min cycles) at 37ºC in the absence or presence of (a) B-crystallin, or (b) Hsp27. 
The amount of ThT fluorescence (excitation at 440 nm and emission at 490nm) was 
monitored over time using a microplate-reader and the change in ThT fluorescence is reported 
as a mean ± SEM of three replicates. The data is representative of at least 3 independent 
experiments. Molar ratios (SOD1: chaperone) are shown on the right. 
  
Figure 3 –B-crystallin inhibits the in vitro aggregation of WT SOD 1 by forming a 
stable complex. (a) Wild-type SOD1 was incubated at 30 M in 10 mM potassium phosphate 
buffer containing 5 mM EDTA, pH 7.4 whilst shaking (120 rpm for 5 min each cycle, 15 min 
cycles) at 37ºC  in the absence or presence of B-crystallin and the amount of ThT 
fluorescence (excitation at 440 nm and emission at 490nm) was monitored over time using a 
microplate-reader. Molar ratios (SOD1: chaperone) are shown on the right. Inset: The percent 
inhibition of the increase in ThT fluorescence afforded by B-crystallin. Results shown are 
mean ± SEM of three replicates. (b) Size exclusion chromatography and SDS-PAGE of the 
eluate to establish whether B-crystallin prevents WT SOD1 aggregation by forming a 
complex with it. Samples containing non-incubated WT SOD1 (30 M, blue), αB-crystallin  
alone (30 M, purple) or WT SOD 1 and αB-crystallin (at a molar ratio of 1:1 and recovered 
at the end of the assay described in a) (orange) were applied to a Superdex 200 HR 10/30 
column and eluted with PBS at a flow rate of 0.5 mL/min. Eluate from the column was 
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collected into 0.5 mL fractions. The sample loaded onto the column (L) (diluted five-fold 
with PBS) and every second fraction eluting between 8 to 17 mL were subjected to SDS-
PAGE analysis.  (c) Immuno-dot blot used to detect the interaction of αB-crystallin with 
aggregated SOD1. Aggregated WT SOD1 (20 M) was incubated in the absence or presence 
of αB-crystallin (20 M) for 1 h at 37°C. Control samples consisted of buffer alone or αB-
crystallin alone.  All samples were collected and centrifuged for 30 min at 4°C and the soluble 
(S) and pellet (P) fractions separated. Pellet fractions were washed twice with PBS and then 
the soluble and pellet fractions were spotted onto a nitrocellulose membrane in duplicate. 
Membranes were blotted with antibodies specific to SOD1 or αB-crystallin. The results 
shown are representative of two independent experiments.   
  
 
Figure 1
Figure 2
10 20 30
-3
0
3
6
9
12
15
18
21
1:0.0
1:0.01
1:0.1
1:1.0
0:1.0
Time (h)
D
T
h
T
 f
lu
o
re
s
c
e
n
c
e
 (
A
U
)
1:1 1:0.1 1:0.01
0
20
40
60
80
100
Molar ratio (SOD: aB-c)
%
 I
n
h
ib
it
io
n
0 1
0
4
8
12
16
20
5 10 15 20
SOD+aB-c
SOD
aB-c
Elution Volume (mL)
A
b
s
o
rb
a
n
c
e
 a
t 
2
8
0
 n
m
 (
A
U
)
S                 P              S                 P
Buffer
aB-c
SOD
SOD+
aB-c
anti-SOD anti-aB-c
(a)
(b)
(c)
Figure 3
aB-c
SOD
L   8    9   10  11  12  13 14 15 16 17
aB-c
SOD
Figure 3
 
Supplementary Figure 1 –Negative control GST does not inhibit the in vitro aggregation 
of WT SOD1 or form a stable complex with its aggregated form. (a) Wild-type SOD1 
was incubated at 30 µM in 10 mM potassium phosphate buffer containing 5 mM EDTA, pH 
7.4 whilst shaking (120 rpm for 5 min each cycle, 15 min cycles) at 37ºC in the absence or 
presence of GST and the amount of ThT fluorescence (excitation at 440 nm and emission at 
490nm) was monitored over time using a microplate-reader. The molar ratio (SOD1: GST) 
used was 1:1. Inset: The percent inhibition of the increase in ThT fluorescence afforded by 
GST. Results shown are mean ± SEM of three replicates. (b) Immuno-dot blot used to detect 
any interaction of GST with aggregated SOD1. Aggregated WT SOD1 (20 µM) was 
incubated in the absence or presence of GST (20 µM) for 1 h at 37°C. Control samples 
consisted of buffer alone or GST alone.  All samples were collected and centrifuged for 30 
min at 4°C and the soluble (S) and pellet (P) fractions separated. Pellet fractions were washed 
twice with PBS and then the soluble and pellet fractions were spotted onto a nitrocellulose 
membrane in duplicate. Membranes were blotted with antibodies specific to SOD1 or GST. 
The results shown are representative of two independent experiments.  
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